Join the Influenza group to help and get support from people like you.
Influenza News (Page 5)
Related terms: The Flu, Flu
Mortality Higher for COVID-19 Hospitalization Than for Flu in 2023/2024 Season
WEDNESDAY, May 22, 2024 – In fall/winter 2023/2024, the risk for death in patients hospitalized for COVID-19 was greater than the risk for death in patients hospitalized for seasonal influenza,...
Genentech Announces FDA Approval of Xofluza to Treat Influenza in Children Aged Five and Older
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved for children as young as five years of age The FDA also approved Xofluza to prevent influenza in...
BioCryst Announces FDA Approval of Supplemental New Drug Application for Rapivab Expanding Patient Population to Include Children Six Months and Older
RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2021 (GLOBE NEWSWIRE) – BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Food and Drug Administration (FDA) has approved a...
Genentech Announces FDA Approval of Xofluza for the Prevention of Influenza Following Contact With an Infected Person
South San Francisco, CA – November 23, 2020 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a...
Genentech Announces FDA Approval of Xofluza (baloxavir marboxil) for People at High Risk of Developing Influenza-Related Complications
South San Francisco, CA – October 17, 2019 – Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug...
FDA Approves Use of 0.5 mL Dose of Fluzone Quadrivalent (influenza vaccine) in Children as Young as 6 Months of Age
BRIDGEWATER, N.J., Jan. 23, 2019 /PRNewswire/ – The U.S. Food and Drug Administration has approved the use of the 0.5 mL dose of Fluzone Quadrivalent (influenza vaccine) to include children age 6...
FDA Approves Xofluza (baloxavir marboxil) for the Treatment of Acute Uncomplicated Influenza
October 24, 2018 – Today, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older...
Seqirus Receives FDA Approval of Afluria Quadrivalent (Influenza Vaccine) for People Five Years of Age and Older in the U.S.
Cambridge, Mass — September 14, 2017 – Seqirus announced today that the U.S. Food and Drug Administration (FDA) has approved Afluria Quadrivalent (Influenza Vaccine) for use in people five years of a...
GSK Receives FDA Approval for Expanded Indication for FluLaval Quadrivalent (Influenza Vaccine) for Infants 6 Months and Older
18 November 2016 – GSK [LSE/NYSE: GSK] announced today it has received approval from the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research expanding the indication ...
Seqirus Receives FDA Approval for Afluria Quadrivalent (Influenza Vaccine) for People 18 Years of Age and Older
CAMBRIDGE, Mass., Aug. 29, 2016 /PRNewswire/ – Seqirus announced today that the US Food and Drug Administration (FDA) has approved Afluria Quadrivalent (Influenza Vaccine) for use in persons 18...
FDA Approves Rapivab (peramivir) to Treat Influenza Infection
December 22, 2014 – On December 19, the U.S. Food and Drug Administration approved Rapivab (peramivir) to treat influenza infection in adults. Influenza, commonly known as the flu, is a contagious...
FDA Approves Flublok - New Seasonal Influenza Vaccine Made Using Novel Technology
January 16, 2013 – The U.S. Food and Drug Administration today announced that it has approved Flublok, the first trivalent influenza vaccine made using an insect virus (baculovirus) expression...
FDA Expands Tamiflu's Use to Treat Children Younger Than One Year
December 21, 2012 – The U.S. Food and Drug Administration today expanded the approved use of Tamiflu (oseltamivir) to treat children as young as 2 weeks old who have shown symptoms of flu for no...
FDA Approves GlaxoSmithKline's Fluarix Quadrivalent - Four-strain Seasonal Influenza Vaccine for Use in the U.S.
LONDON, Dec. 17, 2012 /PRNewswire/ -- GlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the U.S. Food and Drug Administration (FDA) has approved FLUARIX® QUADRIVALENT (Influenza Virus V...
FDA Approves Flucelvax - First Seasonal Influenza Vaccine Manufactured Using Cell Culture Technology
November 20, 2012 – The U.S. Food and Drug Administration announced today the approval of Flucelvax, the first seasonal influenza vaccine licensed in the United States produced using cultured animal...